Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670876 | 1.00 | LMNA (0.50) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4674228 | 0.77 | LMNA (0.59) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4674225 | 0.77 | LMNA (0.59) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL8103946 | 0.76 | LMNA (0.58) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4673540 | 0.72 | MMP2 (0.55) | LMNAMAPTMEN1KMT2AADAMTS5 | |
| SCHEMBL4673538 | 0.72 | MMP2 (0.55) | LMNAMAPTMEN1KMT2AADAMTS5 | |
| SCHEMBL4671075 | 0.72 | LMNA (0.59) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4671077 | 0.72 | LMNA (0.59) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL6009245 | 0.69 | MGLL (0.54) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL8553326 | 0.69 | L3MBTL1 (0.57) | LMNATP53MAPTL3MBTL1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951667-A2 | THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007062078-A2 | THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |